| Market Cap | 475.51M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -32.22M | Forward P/E | - | EPS next Y | - | 50D Avg Chg | 17.00% |
| Sales | 864k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 73.00% |
| Dividend | N/A | Price/Book | 5.18 | EPS next 5Y | - | 52W High Chg | -11.00% |
| Recommedations | - | Quick Ratio | 13.34 | Shares Outstanding | 157.45M | 52W Low Chg | 3,772.00% |
| Insider Own | 17.25% | ROA | -41.35% | Shares Float | 116.06M | Beta | - |
| Inst Own | 2.75% | ROE | -73.59% | Shares Shorted/Prior | -/- | Price | 3.02 |
| Gross Margin | -36.00% | Profit Margin | - | Avg. Volume | 714,110 | Target Price | - |
| Oper. Margin | -3,592.01% | Earnings Date | - | Volume | 864,336 | Change | 0.00% |
Cybin Inc., a biotechnology company, focuses on developing psychedelic therapeutics to treat various psychiatric and neurological conditions. The company operates through two segments, Serenity Life and Cybin U.S., and Natures Journey. The Serenity Life and Cybin U.S. segment engages in the research and development of psychedelic pharmaceutical products. The Natures Journey segment focuses on non-psychedelic medicinal mushroom nutraceutical products. It develops CYB001, a drug candidate that is in phase IIa/b for major depressive disorder; CYB003, a deuterated tryptamine preclinical program to treat alcohol use disorder; CYB004, a deuterated tryptamine preclinical program for therapy resistant psychiatric disorder; and CYB005, a phenethylamine preclinical program for psychiatry and neurology. The company offers its products through various form factors, such as capsules, powders, and effervescent tablets. Cybin Inc. is headquartered in Toronto, Canada.